Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients-Reference-Cited by-同舟云学术

Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients

Published:2010-12-10 Issue:2 Volume:102 Page:478-483
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:

Author:

Chuah Benjamin,Goh Boon-Cher,Lee Soo-Chin,Soong Richie,Lau Fayce,Mulay Marilyn,Dinolfo Melissa,Lim Siew-Eng,Soo Ross,Furuie Taro,Saito Kaku,Zergebel Christopher,Rosen Lee S.

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2010.01793.x/fullpdf

Reference26 articles.

1. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators;Shirasaka;Anticancer Drugs,1996

2. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine;Sakuramoto;N Eng J Med,2007

3. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug;Hirata;Clin Cancer Res,1999

4. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors;van Groeningen;J Clin Oncol,2000

5. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors;Hoff;Clin Cancer Res,2003

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study;The Oncologist;2024-07-11

2. Adjuvant treatment for locally advanced gastric cancer: an Asian perspective;Gastric Cancer;2024-03-15

3. C-Reactive Protein-to-Albumin Ratio to Predict Tolerability of S-1 as an Adjuvant Chemotherapy in Pancreatic Cancer;Cancers;2024-02-25

4. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial;Oncology Letters;2024-02-19

5. Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114);Oncology Research and Treatment;2024